Abstract: The disclosure is directed to a polymeric material formed of a composition including polyalkylsiloxane and a radiation resistant component. The radiation resistant component is included in an amount of about 0.1 wt % to about 20 wt % based on the weight of the polyalkylsiloxane.
Abstract: Disclosed is a method of treating human immunodeficiency virus (HIV) infection in an antiretroviral treatment-experienced mammal, which involves administering to the mammal an effective amount of a compound of the formula: or a pharmaceutically acceptable salt, a prodrug, or an ester thereof, or a pharmaceutically acceptable composition of the compound, the salt, the prodrug, or the ester thereof, wherein A, X, Q, W, m, and R2-R6 are as defined herein.
Type:
Grant
Filed:
October 11, 2007
Date of Patent:
December 3, 2013
Assignees:
The United States of America, as represented by the Secretary, Department of Health and Human Services, Board of Trustees of the University of Illinois
Inventors:
John W. Erickson, Sergei V. Gulnik, Hiroaki Mitsuya, Arun K. Ghosh
Abstract: The present invention refers to a new compound containing Silymarin with Carbopol for the treatment of Diabetes Mellitus. This compound morphologically and structurally regenerates the damage that occurs in the pancreatic tissue in Diabetes Mellitus, and regenerates the insulin-producing pancreatic cells (? cells). It therefore regulates the serum levels of this hormone. Furthermore, it restores and maintains the normal concentrations of the blood glucose.
Abstract: Ophthalmic pharmaceutical compositions containing tobramycin, dexamethasone and deacetylated xanthan gum are described. The compositions provide longer ocular retention for enhanced ocular bioavailability of tobramycin and dexamethasone. In a preferred embodiment, the compositions also provide for improved suspension of dexamethasone. The concentration of ionizable species in the compositions is controlled so as to prevent precipitation of the xanthan gum as a result of ionic interactions between tobramycin and xanthan gum, while allowing for a restoration of viscosity upon topical application of the compositions to the eye. The use of deacetylated xanthan gum is disclosed, so as to avoid formulation instability caused by pH drift during storage.
Abstract: To provide a preventive or ameliorating agent for liver diseases associated with hepatopathy comprising an omega-9 unsaturated fatty acid as an active ingredient.
Abstract: In this application, an antiobesity or antihyperlipidemic food, feeding stuff or supplement containing lysine component(s) that is characterized in that said food, feeding stuff or supplement contains lysine component(s) at such rate that 40 to 160 mg in terms of free-form lysine should be taken in per kg of body weight per day, under diet conditions under which the daily protein energy composition is 20% or less, and an antiobesity or antihyperlipidemic food, feeding stuff or supplement containing lysine component(s) that is characterized by containing said lysine component(s) in an amount of 0.8 to 3.0 wt % in terms of free-form lysine on the basis of the dry matter and having a protein energy composition of 20% or less are disclosed.
Abstract: Trans-platinum compounds comprising carboxylato groups are disclosed, with anti-cancer usefulness. The carboxylato groups participate in solubilizing trans-platinum compounds to which they are attached.
Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula I, A-B-D-E-F-(G)r-(K)s-L??(I), and acid salts thereof, wherein A, B, D, E, F, G and K are ?-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a ?-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.
Type:
Grant
Filed:
December 29, 2009
Date of Patent:
April 24, 2012
Assignee:
Abbott GmbH & Co. KG
Inventors:
Bernd Janssen, Teresa Barlozzari, Andreas Haupt, Thomas Zierke, Andreas Kling
Abstract: The present invention relates to methods of treating a cancerous tumor using selective inhibitors of ATP production. The present invention also relates to pharmaceutical preparations comprising such inhibitors and methods for administering them intraarterially directly to a tumor, as well as methods for identifying compositions that selectively inhibitor ATP production for use in the invention.
Type:
Grant
Filed:
January 16, 2009
Date of Patent:
February 21, 2012
Assignee:
John Hopkins University School of Medicine
Inventors:
Young Hee Ko, Jean-Francois Geschwind, Peter L. Pedersen
Abstract: The present invention is directed to compounds, combinations, compositions and methods for enhancing nitric oxide (NO) delivery to target sites, and in particular to muscle, both normal and dystrophic. Enhanced NO delivery according to the present invention may be achieved by using a combination of a muscle relaxant and an NO donor compound, or by using a compound of the invention: formula (I) wherein R1 is H, halo, C1-6 alkoxy or C1-6 alkyl; R2 is H, NO2 or C(O)NH2; R3 is H, NO2 or C(O)NH2; and at least one of R2 and R3 is NO2; or a pharmaceutically acceptable salt of the compound.
Type:
Grant
Filed:
June 8, 2006
Date of Patent:
January 31, 2012
Inventors:
Gu-Qi Wang, Frank J Burczynski, Judith E Anderson
Abstract: Methods and compositions are provided for treating proliferative disorders, wherein the composition comprises at least one compound according to Formula I: wherein R1 is selected from the group consisting of —OH, —NH2, —NH—CH2—CO2H, —NH—CH(CH3)—CO2H, and —NH—C(CH3)2—CO2H, or a pharmaceutically acceptable salt of such a compound; and an anthracycline, e.g. doxorubicin, or a pharmaceutically acceptable salt thereof, or a platin, e.g. oxaliplatin, or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
March 10, 2006
Date of Patent:
January 31, 2012
Assignees:
Temple University - Of The Commonwealth System of Higher Education, Mount Sinai School of Medicine
Abstract: Ophthalmic pharmaceutical compositions containing tobramycin, dexamethasone and deacetylated xanthan gum are described. The compositions provide longer ocular retention for enhanced ocular bioavailability of tobramycin and dexamethasone. In a preferred embodiment, the compositions also provide for improved suspension of dexamethasone. The concentration of ionizable species in the compositions is controlled so as to prevent precipitation of the xanthan gum as a result of ionic interactions between tobramycin and xanthan gum, while allowing for a restoration of viscosity upon topical application of the compositions to the eye. The use of deacetylated xanthan gum is disclosed, so as to avoid formulation instability caused by pH drift during storage.
Abstract: Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO.
Type:
Grant
Filed:
May 28, 2009
Date of Patent:
December 20, 2011
Assignee:
Galderma Research & Development
Inventors:
Marie-line Abou-Chacra Vernet, Denis Gross, Christian Loesche, Michel Poncet
Abstract: Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO.
Type:
Grant
Filed:
January 13, 2009
Date of Patent:
December 6, 2011
Assignee:
Galderma Research & Development
Inventors:
Marie-line Abou-Chacra Vernet, Denis Gross, Christian Loesche, Michel Poncet
Abstract: According to an aspect of the present invention, implantable or insertable medical devices are provided, which contain polymeric release regions that control the release of one or more therapeutic agents. The polymeric release regions, in turn, contain one or more polymers that contain one or more rigid, nonplanar polycyclic molecular structures. The therapeutic agent is disposed beneath or within the polymeric release region.
Type:
Grant
Filed:
March 14, 2005
Date of Patent:
November 29, 2011
Assignee:
Boston Scientific Scimed, Inc.
Inventors:
Shrirang V. Ranade, Michael N. Helmus, Robert E. Richard
Abstract: The invention relates to the use of a composition comprising kappa opioid receptor antagonists for producing a drug for the treatment of dissociative disorders in humans.
Abstract: The present invention relates to the treatment or prevention of neurodegenerative polyglutamine diseases by the administration of effective amounts of L-methionine S-sulfoximine, L-ethionine S-sulfoximine, glufosinate and/or branched chain ?-keto acids. In particular, the present invention relates to the treatment or prevention of Huntington's disease and other polyglutamine disorders caused by expanded genomic CAG nucleotides.
Abstract: The present invention provides stable pharmaceutical compositions of poorly water soluble pharmaceutical agents and stabilizing agents which function to increase stability of the compositions. The use of stabilizing agents provide extended stability of nanoparticle suspensions and other formulations of poorly water soluble pharmaceutical agents such as docetaxel under certain conditions, for example upon dilution for administration.
Type:
Grant
Filed:
August 30, 2006
Date of Patent:
October 11, 2011
Assignee:
Abraxis BioScience, LLC
Inventors:
Tapas De, Neil P. Desai, Andrew Yang, Zachary Yim, Patrick Soon-Shiong
Abstract: The present invention relates to naphthalene derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine.
Type:
Grant
Filed:
July 26, 2007
Date of Patent:
September 27, 2011
Assignee:
Glaxo Group Limited
Inventors:
Gerard Martin Paul Giblin, Mark Patrick Healy, Helen Susanne Price
Abstract: Adenosine A2A receptor antagonists are useful for the preparation of medicaments against atrial fibrillation in mammals, including humans. It has been found that the adenosine A2A receptor is present in human atrial cardiomyocytes and participates in the pathological mechanisms underlying atrial fibrillation. An advantage of using A2A antagonists over other agents known in the art is that the A2A antagonists specifically target patients with atrial fibrillation.
Type:
Grant
Filed:
October 10, 2006
Date of Patent:
September 6, 2011
Assignee:
Proyecto de Biomedicina Cima S.L.
Inventors:
Rafael Franco Fernández, Franciso Ciruela Alférez, Carmen Lluís Biset, Christa Müller, Joan Cinca Cuscullola, Leif Hove-Madsen